(Q54609676)

1 June 2018

title

Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. (English)

1 reference

1 June 2018

1 reference

B Y S Chuah

1

1 reference

1 June 2018

T Putti

2

1 reference

1 June 2018

M Salto-Tellez

3

1 reference

1 June 2018

A Charlton

4

1 reference

1 June 2018

P Iau

5

1 reference

1 June 2018

S A Buhari

6

1 reference

1 June 2018

C I Wong

7

1 reference

1 June 2018

S H Tan

8

1 reference

1 June 2018

A L A Wong

9

1 reference

1 June 2018

C W Chan

10

1 reference

1 June 2018

B C Goh

11

1 reference

1 June 2018

S C Lee

12

1 reference

1 June 2018

publication date

25 February 2011

1 reference

1 June 2018

published in

Annals of Oncology

1 reference

1 June 2018

volume

22

1 reference

1 June 2018

issue

8

1 reference

1 June 2018

page(s)

1748-1754

1 reference

1 June 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

The contributions of cyclooxygenase-2 to tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer Is Rare

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ755

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ755

1 reference

1 June 2018

release_rkmaajx4rrauzkctksbpyhpike

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rkmaajx4rrauzkctksbpyhpike

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

1 June 2018